Sera Prognostics to Report Q3 2026 Results on November 4
The diagnostic company will hold a conference call to discuss its operational performance for the recent fiscal quarter.
Updated on Oct. 21, 2026 in Economic Indicators
Live Poll
Do you trust quarterly corporate earnings reports as a reliable indicator of a company's long-term health?
Salt Lake City-based diagnostics firm Sera Prognostics will report its third quarter fiscal year 2026 financial results on November 4, 2026. The company, which produces the PreTRM test to predict preterm birth risks, will discuss its operational performance during a scheduled conference call.
Why it matters
The company operates in a sector addressing significant healthcare costs, which reached an estimated $25 billion in 2016. Monitoring these financial results helps investors and local stakeholders understand the market adoption of diagnostic tests intended to mitigate preterm birth risks in a country recently graded D+ by the March of Dimes.
Healthcare costs for prematurity complications were estimated at $25 billion as of 2016. The United States recently received a D+ grade in the 2025 March of Dimes Report Card, highlighting ongoing challenges in managing births occurring before 37 weeks gestation.
The players
Sera Prognostics
A Salt Lake City-based diagnostics company that develops blood-based tests to predict preterm birth risks.
March of Dimes
A national nonprofit organization that evaluates preterm birth rates and issues annual report cards on reproductive health outcomes.
The details
Sera Prognostics develops the PreTRM test, a diagnostic tool ordered between 18 and 20 weeks of pregnancy to predict the risk of preterm delivery. The upcoming financial reporting session will provide insight into the commercial scale of this protein-based blood analysis. Management will host a conference call at 5:00 p.m. ET to detail the company's operating performance for the third quarter.
Timeline
Annual healthcare costs for prematurity were estimated at $25 billion in 2016.
The United States received a D+ grade in the 2025 March of Dimes Report Card.
Sera Prognostics will report its Q3 2026 financial results on November 4, 2026.
The conference call will be held at 5:00 p.m. ET on November 4, 2026.
Market Landscape
Sera Prognostics' market position is influenced by the persistent clinical challenges identified in the 2025 March of Dimes Report Card. This reporting event provides a corporate-level view on the commercial efforts to address the outcomes measured by that framework.
Operators in the healthcare and diagnostics space should track these results to gauge market demand for preventative testing services. Financial analysts and local partners should monitor the company's operational trajectory for indicators of wider industry adoption.
The takeaway
The diagnostic market remains highly sensitive to clinical outcomes and national healthcare grading metrics. Operators should watch for revenue shifts in next-quarter disclosures to determine if current diagnostic tools are effectively penetrating the market for high-risk pregnancies.
What happens next
Sera Prognostics will host a conference call for investors and analysts at 5:00 p.m. ET on November 4, 2026.
Further reading
For broader trends in local industry performance, see Economic Indicators.
More information
Interested parties can access the conference call and webcast registration for the upcoming financial results announcement.
Source note: This article includes information reported by The Herald Journal.
Live Poll
Do you trust quarterly corporate earnings reports as a reliable indicator of a company's long-term health?
